ATE90877T1 - Virusmodifizierte tumorvakzinen fuer die immuntherapie von tumormetastasen. - Google Patents

Virusmodifizierte tumorvakzinen fuer die immuntherapie von tumormetastasen.

Info

Publication number
ATE90877T1
ATE90877T1 AT89103480T AT89103480T ATE90877T1 AT E90877 T1 ATE90877 T1 AT E90877T1 AT 89103480 T AT89103480 T AT 89103480T AT 89103480 T AT89103480 T AT 89103480T AT E90877 T1 ATE90877 T1 AT E90877T1
Authority
AT
Austria
Prior art keywords
pct
virus
tumor
vaccine
immunotherapy
Prior art date
Application number
AT89103480T
Other languages
German (de)
English (en)
Inventor
Volker Prof Dr Schirrmacher
Original Assignee
Deutsches Krebsforsch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6348527&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE90877(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Deutsches Krebsforsch filed Critical Deutsches Krebsforsch
Application granted granted Critical
Publication of ATE90877T1 publication Critical patent/ATE90877T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT89103480T 1988-03-01 1989-02-27 Virusmodifizierte tumorvakzinen fuer die immuntherapie von tumormetastasen. ATE90877T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3806565A DE3806565A1 (de) 1988-03-01 1988-03-01 Virusmodifizierte tumorvakzinen fuer die immuntherapie von tumormetastasen
EP19890103480 EP0331102B1 (de) 1988-03-01 1989-02-27 Virusmodifizierte Tumorvakzinen für die Immuntherapie von Tumormetastasen

Publications (1)

Publication Number Publication Date
ATE90877T1 true ATE90877T1 (de) 1993-07-15

Family

ID=6348527

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89103480T ATE90877T1 (de) 1988-03-01 1989-02-27 Virusmodifizierte tumorvakzinen fuer die immuntherapie von tumormetastasen.

Country Status (10)

Country Link
US (1) US5273745A (OSRAM)
EP (1) EP0331102B1 (OSRAM)
JP (1) JPH02504034A (OSRAM)
KR (1) KR900700130A (OSRAM)
AT (1) ATE90877T1 (OSRAM)
AU (1) AU3188989A (OSRAM)
DE (2) DE3806565A1 (OSRAM)
DK (1) DK541889A (OSRAM)
ES (1) ES2042828T3 (OSRAM)
WO (1) WO1989007946A1 (OSRAM)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3922444A1 (de) * 1988-03-01 1991-01-10 Deutsches Krebsforsch Virusmodifizierte tumorvakzine fuer die immuntherapie von tumormetastasen
DE4204132C2 (de) * 1991-02-12 1997-12-18 Rudolf Dr Pekar Aufbereitung für die Gewinnung von Vakzinen für eine Immuntherapie
JP3580371B2 (ja) * 1991-10-04 2004-10-20 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ サイトカインおよび抗原を用いた全身の免疫応答の調節
CA2161671A1 (en) 1993-04-30 1994-11-10 Robert M. Lorence Methods of treating and detecting cancer using viruses
DE19506483A1 (de) * 1995-02-24 1996-08-29 Jens Dr Dr Atzpodien Lyophilisat-Vakzine
US6406689B1 (en) 1995-10-03 2002-06-18 Frank W. Falkenberg Compositions and methods for treatment of tumors and metastatic diseases
EP0805207A1 (en) * 1996-05-02 1997-11-05 Gesellschaft für Biotechnologische Forschung mbH (GBF) Polycistronic expression plasmid for tumor rejection
DE69723580T2 (de) * 1996-05-03 2004-06-03 Thomas Jefferson University Impfstoff gegen metastasierenden kolorektalkrebs.
CA2242590A1 (en) * 1996-10-04 1998-04-09 Thomas Jefferson University T cells mediating an immune response and methods of use
DE69731950T2 (de) * 1997-08-22 2005-05-19 Science Park Raf S.P.A. Tumorvakzinierung mittels Verwendung autologer oder HLA-verwandter Antigen präsentierender Zellen (APC), die mit einem Tumorantigen sowie einem eine Immunantwort hervorrufenden Fremdantigen transduziert sind
TW575420B (en) * 1997-09-22 2004-02-11 Kirin Brewery Composition for enhancing cellular immunogenicity comprising alpha-glycosylceramides
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
US7780962B2 (en) * 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US20030044384A1 (en) * 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
CN1477964A (zh) * 1999-04-15 2004-02-25 应用病毒治疗肿瘤
US8147822B1 (en) * 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
EP1092439A1 (en) * 1999-10-13 2001-04-18 Thorsten Dr. Ahlert Activation of antigen-specific T cells by virus/antigen-treated dendritic cells
RU2172182C1 (ru) * 2000-07-27 2001-08-20 Бритов Василий Александрович Способ профилактики и лечения заболеваний иммунной системы и средство для его осуществления
WO2004096244A1 (en) * 2003-05-02 2004-11-11 Md Bioalpha Co. Ltd. Method of preparing tumor vaccine for the inducement of anti-tumor activity and a pharmaceutical composition containing the same
EA016217B1 (ru) 2005-12-02 2012-03-30 Маунт Синай Скул Оф Медсин Химерные вирусы, представляющие неприродные поверхностные белки, и их применение
US9283266B2 (en) * 2008-02-28 2016-03-15 University Of Notre Dame Metastasis inhibition preparations and methods
JPWO2010030002A1 (ja) 2008-09-12 2012-02-02 国立大学法人三重大学 外来性ｇｉｔｒリガンド発現細胞
US20110206736A1 (en) * 2008-09-23 2011-08-25 Thomas Jefferson University Cancer Vaccines Against Mucosal Antigens and Methods of Making and Using the Same
ES2380289T3 (es) * 2009-11-30 2012-05-10 United Cancer Research Institute Nuevo clon del virus de la enfermedad de Newcastle, su fabricación y aplicación en el tratamiento médico del cáncer
WO2014158811A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Newcastle disease viruses and uses thereof
SG11201607130RA (en) 2014-02-27 2016-09-29 Viralytics Ltd Combination method for treatment of cancer
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
US12391957B2 (en) 2018-08-17 2025-08-19 Icahn School Of Medicine At Mount Sinai Recombinant Newcastle disease viruses and uses thereof for the prevention of RSV disease or human metapneumovirus disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2918927A1 (de) * 1979-05-10 1980-11-20 Hans Prof Dr Limburg Arzneipraeparat zur behandlung von carcinomen und verfahren zu dessen herstellung
DE3432714A1 (de) * 1984-09-06 1986-04-24 Behringwerke Ag, 3550 Marburg Tumortherapeutikum und verfahren zu seiner herstellung
HU197517B (en) * 1984-07-30 1989-04-28 Laszlo Csatary Process for production of terapeutical composition applicable against virus infection

Also Published As

Publication number Publication date
JPH02504034A (ja) 1990-11-22
EP0331102B1 (de) 1993-06-23
DE3806565A1 (de) 1989-09-14
AU3188989A (en) 1989-09-22
WO1989007946A1 (fr) 1989-09-08
EP0331102A1 (de) 1989-09-06
US5273745A (en) 1993-12-28
DE58904760D1 (de) 1993-07-29
DK541889D0 (da) 1989-10-31
DE3806565C2 (OSRAM) 1991-04-25
ES2042828T3 (es) 1993-12-16
KR900700130A (ko) 1990-08-11
DK541889A (da) 1989-10-31

Similar Documents

Publication Publication Date Title
ATE90877T1 (de) Virusmodifizierte tumorvakzinen fuer die immuntherapie von tumormetastasen.
DE69030172D1 (de) Impfstoffe gegen Krebs und Infektionskrankheiten
ATE306939T1 (de) Mehrstufiger kaskade-erhöhungsimpfstoff
ATE326479T1 (de) Varianten von antigenen des menschlichen papillomvirus
ATE105334T1 (de) Schimaerische glykoproteine enthaltende immunogenische abschnitte von menschlichem parainfluenzavirus typ 3.
FI950665A0 (fi) Melanoomaan liittyvä antigeeninen polypeptidi, sen epitooppeja ja melanoomarokotteita
ATE260666T1 (de) Zellulärer impfstoff und deren verwendung für die behandlung von malignen, soliden tumoren
DE69934426D1 (de) KREBSIMMUNTHERAPIE UND KREBSDIAGNOSE UNTER VERWENDUNG UNIVERSELLER TUMORASSOZIIERTER ANTIGENE EINSCHLIESSLICH hTERT
ATE391726T1 (de) Modifiziertes gp100 und dessen verwendung
ATE402713T1 (de) Genetisch manipulierte herpesviren zur behandlung von tumoren
DK0889969T3 (da) Rekombinante adenovirale til genterapi af humane tumorer
ES553425A0 (es) Perfeccionamientos en la fabricacion de conjugados de proteinas portadores de antigenos inmunogenicos para vacunas contra la malaria
ES523029A0 (es) Procedimiento para el ahorro de energia en la preparacion de tio2.
ES546701A0 (es) Procedimiento para preparar un agente terapeutico a base de celulas tumorales humanas y eventualmente, neuraminidasa.
AR015237A1 (es) Una composicion de membranas celulares tumorales modificadas con hapteno, metodo para obtenerlas y su uso.
DE68917138D1 (de) Toleranzinduktion gegenüber einem fremdantigen.
BR9306187A (pt) Vacina bacterin-toxóide pasteurella haemolytica tipo a-1
ES2051721T3 (es) Productos activos para impedir las metastasis tumorales.
ES550089A0 (es) Procedimiento para producir una vacuna coadyuvada que contiene un antigeno seleccionado de proteinas, bacterias y virus.
IT1187642B (it) Emoglobina a ridotti rischi da virus e procedimento per prepararla
SE8700466D0 (sv) Vaccines against melanoma
IT1254147B (it) Metodo di rivelazione di marcatori tumorali.
IL81475A0 (en) Newcastle disease virus(ndv)vaccine and method for the application thereof
IL85266A0 (en) Newcastle disease virus(ndv)vaccine and method for the application thereof